<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLoS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29474364</article-id>
<article-id pub-id-type="pmc">5825026</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0192151</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-27858</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Nucleic acids</subject>
<subj-group>
<subject>RNA</subject>
<subj-group>
<subject>Messenger RNA</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Molecular Biology</subject>
<subj-group>
<subject>Molecular Biology Techniques</subject>
<subj-group>
<subject>Artificial Gene Amplification and Extension</subject>
<subj-group>
<subject>Polymerase Chain Reaction</subject>
<subj-group>
<subject>Reverse Transcriptase-Polymerase Chain Reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Molecular Biology Techniques</subject>
<subj-group>
<subject>Artificial Gene Amplification and Extension</subject>
<subj-group>
<subject>Polymerase Chain Reaction</subject>
<subj-group>
<subject>Reverse Transcriptase-Polymerase Chain Reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and analysis methods</subject>
<subj-group>
<subject>Extraction techniques</subject>
<subj-group>
<subject>RNA extraction</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Toxicology</subject>
<subj-group>
<subject>Toxicity</subject>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Pathology and Laboratory Medicine</subject>
<subj-group>
<subject>Toxicology</subject>
<subj-group>
<subject>Toxicity</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Molecular Biology</subject>
<subj-group>
<subject>Molecular Biology Techniques</subject>
<subj-group>
<subject>Artificial Gene Amplification and Extension</subject>
<subj-group>
<subject>Polymerase Chain Reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Molecular Biology Techniques</subject>
<subj-group>
<subject>Artificial Gene Amplification and Extension</subject>
<subj-group>
<subject>Polymerase Chain Reaction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Mathematical and Statistical Techniques</subject>
<subj-group>
<subject>Statistical Methods</subject>
<subj-group>
<subject>Regression Analysis</subject>
<subj-group>
<subject>Linear Regression Analysis</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical Sciences</subject>
<subj-group>
<subject>Mathematics</subject>
<subj-group>
<subject>Statistics (Mathematics)</subject>
<subj-group>
<subject>Statistical Methods</subject>
<subj-group>
<subject>Regression Analysis</subject>
<subj-group>
<subject>Linear Regression Analysis</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Body Fluids</subject>
<subj-group>
<subject>Blood</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Anatomy</subject>
<subj-group>
<subject>Body Fluids</subject>
<subj-group>
<subject>Blood</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Physiology</subject>
<subj-group>
<subject>Body Fluids</subject>
<subj-group>
<subject>Blood</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Medicine and Health Sciences</subject>
<subj-group>
<subject>Physiology</subject>
<subj-group>
<subject>Body Fluids</subject>
<subj-group>
<subject>Blood</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and analysis methods</subject>
<subj-group>
<subject>Chemical synthesis</subject>
<subj-group>
<subject>Biosynthetic techniques</subject>
<subj-group>
<subject>Nucleic acid synthesis</subject>
<subj-group>
<subject>RNA synthesis</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Nucleic acids</subject>
<subj-group>
<subject>RNA</subject>
<subj-group>
<subject>RNA synthesis</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>β-glucuronidase use as a single internal control gene may confound analysis in <italic>FMR1</italic> mRNA toxicity studies</article-title>
<alt-title alt-title-type="running-head">Limitations of <italic>GUS</italic> normalisation for <italic>FMR1</italic> mRNA analysis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1805-6339</contrib-id>
<name>
<surname>Kraan</surname>
<given-names>Claudine M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cornish</surname>
<given-names>Kim M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bui</surname>
<given-names>Quang M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xin</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slater</surname>
<given-names>Howard R.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Godler</surname>
<given-names>David E.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Cyto-molecular Diagnostic Research Laboratory, Victorian Clinical Genetics Services and Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, Victoria, Australia</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, Victoria, Australia</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia</addr-line></aff>
<aff id="aff004"><label>4</label>
<addr-line>Centre for Epidemiology and Biostatistics, University of Melbourne Carlton, Victoria, Australia</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Fernandez-Funez</surname>
<given-names>Pedro</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Minnesota Duluth, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email>david.godler@mcri.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>2</issue>
<elocation-id>e0192151</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© 2018 Kraan et al</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Kraan et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pone.0192151.pdf"></self-uri>
<abstract>
<p>Relationships between Fragile X Mental Retardation 1 (<italic>FMR1</italic>) mRNA levels in blood and intragenic <italic>FMR1</italic> CGG triplet expansions support the pathogenic role of RNA gain of function toxicity in premutation (PM: 55–199 CGGs) related disorders. Real-time PCR (RT-PCR) studies reporting these findings normalised <italic>FMR1</italic> mRNA level to a single internal control gene called <italic>β</italic>-glucuronidase (<italic>GUS)</italic>. This study evaluated <italic>FMR1</italic> mRNA-CGG correlations in 33 PM and 33 age- and IQ-matched control females using three normalisation strategies in peripheral blood mononuclear cells (PBMCs): (i) <italic>GUS</italic> as a single internal control; (ii) the mean of <italic>GUS</italic>, Eukaryotic Translation Initiation Factor 4A2 <italic>(EIF4A2</italic>) and succinate dehydrogenase complex flavoprotein subunit A (<italic>SDHA</italic>); and (iii) the mean of <italic>EIF4A2</italic> and <italic>SDHA</italic> (with no contribution from <italic>GUS</italic>). <italic>GUS</italic> mRNA levels normalised to the mean of <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels and <italic>EIF4A2</italic>/<italic>SDHA</italic> ratio were also evaluated. <italic>FMR1</italic>mRNA level normalised to the mean of <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels, with no contribution from <italic>GUS</italic>, showed the most significant correlation with CGG size and the greatest difference between PM and control groups (<italic>p</italic> = 10<sup>−11</sup>). Only 15% of <italic>FMR1</italic> mRNA PM results exceeded the maximum control value when normalised to <italic>GUS</italic>, compared with over 42% when normalised to the mean of <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels. Neither <italic>GUS</italic> mRNA level normalised to the mean RNA levels of <italic>EIF4A2</italic> and <italic>SDHA</italic>, nor to the <italic>EIF4A2/SDHA</italic> ratio were correlated with CGG size. However, greater variability in <italic>GUS</italic> mRNA levels were observed for both PM and control females across the full range of CGG repeat as compared to the <italic>EIF4A2/SDHA</italic> ratio. In conclusion, normalisation with multiple control genes, excluding <italic>GUS</italic>, can improve assessment of the biological significance of <italic>FMR1</italic> mRNA-CGG size relationships.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003752</institution-id>
<institution>Centre of Excellence in Cognition and its Disorders, Australian Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>DP110103346</award-id>
<principal-award-recipient>
<name>
<surname>Cornish</surname>
<given-names>Kim M.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
<institution>National Health and Medical Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>104299</award-id>
<principal-award-recipient>
<name>
<surname>Godler</surname>
<given-names>David E.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
<institution>National Health and Medical Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>1103389</award-id>
<principal-award-recipient>
<name>
<surname>Godler</surname>
<given-names>David E.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000925</institution-id>
<institution>National Health and Medical Research Council</institution>
</institution-wrap>
</funding-source>
<award-id>1112934</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1805-6339</contrib-id>
<name>
<surname>Kraan</surname>
<given-names>Claudine M.</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This study was supported by an Australian Research Council (ARC) Discovery grant (DP110103346) to K.M.C, an Australian Postgraduate Award Scholarship, Monash University Faculty of Medicine, Nursing and Health Sciences Bridging Postdoctoral Fellowship and NHMRC Early Career fellowship to C.M.K. (no. 1112934); a Next Generation Clinical Researchers Program - Career Development Fellowship, funded by the Medical Research Future Fund (MRFF 1141334) to D.E.G.; and by the Victorian Government’s Operational Infrastructure Support Program, with the salaries for the molecular component supported by NHMRC project grants (no. 104299, and no. 1103389 to H.R.S. and D.E.G.) and Murdoch Children’s Research Institute, Royal Children’s Hospital Foundation (D.E.G.). The authors thank the Fragile X Association of Australia and Fragile X Alliance for supporting recruitment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"></fig-count>
<table-count count="1"></table-count>
<page-count count="11"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are found in paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All relevant data are found in paper and its Supporting Information files.</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>The prevalence of <italic>FMR1</italic> Premutation (PM: CGG 55–199) alleles in the general population has been reported to be as high as 1 in 150 females and 1 in 450 males [<xref ref-type="bibr" rid="pone.0192151.ref001">1</xref>]. Maternally transmitted PM alleles have the propensity to expand in future generations to full mutation (CGG ≥200) alleles that cause fragile X syndrome (FXS) [<xref ref-type="bibr" rid="pone.0192151.ref002">2</xref>]. FXS is a common cause of intellectual disability and co-morbid autism (reviewed in [<xref ref-type="bibr" rid="pone.0192151.ref003">3</xref>]). PM alleles have also been associated with adult onset Fragile X-associated disorders: Fragile X-associated tremor/ataxia syndrome (FXTAS: 40% males and 8–16% females over 50 years old) and Fragile X-associated primary ovarian insufficiency (FXPOI: ~20% females) [<xref ref-type="bibr" rid="pone.0192151.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0192151.ref005">5</xref>]. Pathogenic mechanisms suggested to cause PM related disorders include reduced <italic>FMR1</italic> protein expression (FMRP), elevated levels of non-coding RNA (<italic>FMR4</italic>, <italic>FMR5</italic>, <italic>FMR6</italic>) [<xref ref-type="bibr" rid="pone.0192151.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0192151.ref007">7</xref>], mitochondrial dysfunction [<xref ref-type="bibr" rid="pone.0192151.ref008">8</xref>] and CGG repeat-associated non-AUG translation [<xref ref-type="bibr" rid="pone.0192151.ref009">9</xref>]. The mechanism most extensively studied in the context of Fragile X-associated disorders is <italic>FMR1</italic> mRNA gain of function toxicity [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>].</p>
<p><italic>FMR1</italic> mRNA levels in the blood have been reported to be elevated 2–8 fold in PMs as compared to individuals with normal <italic>FMR1</italic> alleles (&lt;45 CGG repeats). This finding has been replicated across many different cell types in humans and in various CGG knock-in animal models [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192151.ref011">11</xref>]. It is thought that this PM-specific <italic>FMR1</italic> mRNA excess is indirectly associated with increase in CGG size in the PM range and the formation of intranuclear inclusion bodies and late-onset neurodegeneration [<xref ref-type="bibr" rid="pone.0192151.ref012">12</xref>]. Indeed, PM-size ribo-rCGG repeat containing <italic>FMR1</italic> mRNA can induce formation of intranuclear inclusions in Purkinje neurons of the cerebellum in transgenic mice, also known as nuclear foci [<xref ref-type="bibr" rid="pone.0192151.ref013">13</xref>]. Moreover, inclusion bodies that stain positive for <italic>FMR1</italic> mRNA have been found in both the central nervous system of men with FXTAS [<xref ref-type="bibr" rid="pone.0192151.ref014">14</xref>–<xref ref-type="bibr" rid="pone.0192151.ref016">16</xref>] and in mice with ‘knock in’ PM alleles [<xref ref-type="bibr" rid="pone.0192151.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0192151.ref018">18</xref>].</p>
<p><italic>FMR1</italic> mRNA levels in peripheral tissues have been significantly correlated with brain changes associated with FXTAS and with subtle motor signs in adult PM carriers at risk for FXTAS [<xref ref-type="bibr" rid="pone.0192151.ref019">19</xref>–<xref ref-type="bibr" rid="pone.0192151.ref021">21</xref>]. However, other studies failed to identify any relationship between the <italic>FMR1</italic> mRNA level and similar clinical outcome measures, even in cases where relationships between the phenotype and CGG size were present [<xref ref-type="bibr" rid="pone.0192151.ref022">22</xref>, <xref ref-type="bibr" rid="pone.0192151.ref023">23</xref>].</p>
<p>The first study to propose the RNA toxicity mechanism used real-time PCR, normalising <italic>FMR1</italic> mRNA levels with <italic>GUS</italic> as a single internal control [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>]. This study reported that normal peripheral blood leukocytes maintain comparable levels of <italic>FMR1</italic> and <italic>GUS</italic> mRNA, although no data was presented examining variability of <italic>GUS</italic> mRNA level as compared to other internal control genes in the control and PM groups.</p>
<p>While <italic>GUS</italic> is commonly used as an internal control gene for RT-PCR normalisation across different settings, especially in plant biology studies, its transcription stability in mammalian systems has been variable between studies and cell types [<xref ref-type="bibr" rid="pone.0192151.ref024">24</xref>–<xref ref-type="bibr" rid="pone.0192151.ref028">28</xref>]. Analysis of <italic>GUS</italic> mRNA stability as compared to other genes in lymphoid malignancies or B and T cell enriched and stimulated leukocyte fractions found that <italic>GUS</italic> had less stable transcription when compared to other internal control genes [<xref ref-type="bibr" rid="pone.0192151.ref029">29</xref>]. More recently, the geNorm approach was used to determine the most stably expressed genes in peripheral blood mononuclear cells (PBMCs) of PM and control males [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>], to determine the ‘optimal’ method for <italic>FMR1</italic> mRNA normalisation. The <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA average was found to be the optimal normalisation method. This normalisation method was then applied to PM and control females, where correlations to the phenotype were also investigated [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>].</p>
<p>This study expands on the previous findings by examining: (i) how the choice of the normalisation method impacts the strength of the previously published correlation between <italic>FMR1</italic> mRNA level and CGG triplet expansion size in PM females and an age and IQ matched group; (ii) the variability in internal control gene mRNA levels including <italic>EIF4A2</italic>, <italic>SDHA</italic> and <italic>GUS</italic> when compared between PM females and an age and IQ-matched control group; (iii) relationships between CGG triplet expansion size and the mRNA levels of the chosen internal control genes.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec003">
<title>Participants</title>
<p>All study participants provided signed informed consent and the study procedures were consistent with the Declaration of Helsinki and approved by the Southern Health Ethics Committee (project 10147B). Participants included 35 PM females and 35 age- and IQ-matched control females recruited as part of previous studies [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]. Groups were matched on height, body mass index (BMI), age and Wechsler Abbreviated Scale of Intelligence (WASI) Full Scale IQ score (see details in [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]). Participants were English speaking with no history of epilepsy or of a serious head injury and had normal (or corrected) vision and hearing, and no sign of colour blindness or intellectual disability (as assessed using the WASI Full Scale IQ score).</p>
</sec>
<sec id="sec004">
<title>CGG triplet expansion sizing</title>
<p>Four millilitres of venous blood were collected in ethylene diaminetetraacetic acid (EDTA_ tubes (BD, worldwide) from all participants. DNA was extracted using the BIO ROBOT M48 DNA Extractor (Qiagen Inc., Hilden, Germany). The CGG sizing was performed using the Asuragen AmplideX™ <italic>FMR1</italic> Polymerase chain reaction (PCR) Kit, as per manufacturer’s recommendations (Asuragen: Austin, TX, USA) [<xref ref-type="bibr" rid="pone.0192151.ref031">31</xref>].</p>
</sec>
<sec id="sec005">
<title>RNA extraction and mRNA analysis</title>
<p>One million peripheral blood mononuclear cells (PBMCs) were isolated per participant from venous blood using Ficoll gradient separation as previously described [<xref ref-type="bibr" rid="pone.0192151.ref007">7</xref>], with PBMC pellets frozen at -80°C in RLT buffer for total RNA extraction. Total RNA was purified using the RNeasy extraction kit, as per manufacturer’s instructions (Qiagen Inc., Hilden, Germany). NanoDrop ND-1000 Spectrophotometer was used to determine RNA concentrations in triplicate, with purity assessed using the A260/A280 ratio (expected values between 1.8 and 2). Each RNA sample was then diluted to 5 ng/μl, with 2 μl RNA added for cDNA synthesis performed using the Multiscribe Reverse Transcription System (20 μl total), 50 units/μl of the reverse transcription enzyme (Life Technologies, Global).</p>
<p>Real-time quantitative PCR (RT-PCR) was performed on a ViiA™ 7 System (Life Technologies, Global) to quantify <italic>FMR1</italic>-5′, <italic>FMR1</italic>-3′ and internal control genes (i.e., <italic>GUS</italic>, <italic>EIF4A2</italic> and <italic>SDHA</italic>) using the relative standard curve method, as previously described [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]. <italic>FMR1</italic>-5′, <italic>FMR1</italic>-3′ and <italic>GUS</italic> primers and probes were used at concentrations of 18 μM and 2 μM, respectively, with previously published sequences for RT-PCR primers and probes for: <italic>FMR1</italic>-5′ [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>], <italic>FMR1</italic>-3′ [<xref ref-type="bibr" rid="pone.0192151.ref032">32</xref>] and <italic>GUS [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>]</italic> assays. Specifically, these sequences included: (i) <italic>FMR1</italic>-5′ forward primer <monospace>5′-GCAGAT TCCATTTCATGATGTCA-3′</monospace>; <italic>FMR1</italic>-5′ reverse primer <monospace>5′-ACCACCAACAGCAAGGCT CT-3'</monospace>; and <italic>FMR1</italic>-5′ probe <monospace>5′-(FAM)-TGA TGA AGT TGA GGT GTA TTC CAG AGC AAA TGA-(TAMRA)-3′</monospace>; (ii) <italic>FMR1</italic>-3′ forward primer <monospace>5′-GGAACAAAGGACAGCATCGC-3′</monospace>; <italic>FMR1</italic>-3′ reverse primer <monospace>5′-CTCTCCAAACGCAACTGGTCT-3′</monospace>; <italic>FMR1</italic>-3’ probe <monospace>5′-(FAM)-AATGCCACTGTTCTTTTGGATTATCACCTGAA-(TAMRA)-3′</monospace>; (iii) <italic>GUS</italic> forward primer <monospace>5′-CTCATTTGGAATTTTGCCGAT T-3′</monospace>; <italic>GUS</italic> reverse primer <monospace>5′-CCGAGTGAAGATCCC CTTTTTA-3′</monospace>; <italic>GUS</italic> probe <monospace>5′-(FAM)-TGAACAGTCACCGACGAGAGTGCTGG-(TAMRA)-3′</monospace>. The <italic>FMR1-5’</italic>and 3’assays target <italic>FMR1</italic> exon 3 /4 and exon 13/14 junctions, respectively. These same assays are mRNA specific (do not amplify DNA), targeting conserved regions of <italic>FMR1</italic> mRNA that are not subject to alternative splicing, as described previously [<xref ref-type="bibr" rid="pone.0192151.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0192151.ref032">32</xref>, <xref ref-type="bibr" rid="pone.0192151.ref033">33</xref>].</p>
<p><italic>EIF4A2</italic> and <italic>SDHA</italic> primer/probe mixes were obtained from PrimerDesign (PerfectProbe ge-PP-12-hu kit) and used at concentration of 2 μM, with sequences not disclosed by the manufacturer. The <italic>FMR1</italic>-5′ and <italic>FMR1</italic>-3′ target gene and the internal control gene dynamic linear range (DLR) common to all the assays was determined to be 1 to 40 ng/μl total RNA input in a 20 μl cDNA reaction. This was determined from a series of doubling dilutions of RNA (160–0.5 ng/ul) of a selected control PBMC sample. All assays showed optimal performance within the DLR, with PCR efficiency ranging between 92 and 94% and coefficient of correlation of greater than 0.98. For all assays in this study, samples were quantified in arbitrary units (au) in relation to the standard curves performed on each plate and had to be within the DLR to be included in further analyses. The mean <italic>FMR1</italic> 5’and 3’ mRNA levels was normalised to: (i) <italic>GUS</italic> alone (<italic>FMR1</italic>/<italic>GUS</italic>); (ii) mean of <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels (<italic>FMR1</italic>/2IC); (iii) mean of <italic>GUS</italic>, <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels (<italic>FMR1</italic>/3IC). <italic>GUS</italic> mRNA levels were normalised to 2IC (<italic>EIF4A2</italic> and <italic>SDHA</italic>); while <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA was expressed as a ratio (<italic>EIF4A2/SDHA)</italic>.</p>
<p>Two separate cDNA reactions were performed for each RNA sample, with each cDNA analysed in two separate RT-PCR reactions. The summary measure for mRNA level for each participant was represented by the mean of the four outputs. <italic>FMR1</italic> mRNA results were not obtained for two PM females and two control females from the 70 participants because there was either insufficient RNA extracted or because the results failed the 5′ and 3′ <italic>FMR1</italic> mRNA quality control step [<xref ref-type="bibr" rid="pone.0192151.ref033">33</xref>].</p>
</sec>
<sec id="sec006">
<title>Statistical analyses</title>
<p>The Shapiro-Wilk normality test was used to check normal distribution for each of the <italic>FMR1</italic> mRNA datasets, separately for each group. The data was then transformed if normality was not achieved. <italic>FMR1</italic>/<italic>GUS</italic> data was transformed using a natural logarithm function while for all other data, reciprocal function was used The Generalised estimating (GEE) method was then used for the inter-group comparison, taking into account correlation within family in the PM cohort. For the relationship between each mRNA level and CGG size, piecewise linear regression was used to find a threshold, resulting in two different slopes, above and below the threshold. Analyses were carried out using STATA software. See <xref ref-type="supplementary-material" rid="pone.0192151.s001">S1 Table</xref> for raw data.</p>
</sec>
</sec>
<sec id="sec007" sec-type="results">
<title>Results</title>
<sec id="sec008">
<title>Intergroup comparisons of <italic>FMR1</italic> mRNA levels between PM and control groups</title>
<p>Three different methodologies for normalisation of <italic>FMR1</italic> mRNA levels in blood were compared between PM and control groups: <italic>FMR1</italic>/<italic>GUS</italic>, <italic>FMR1</italic>/3IC and <italic>FMR1</italic>/2IC. <italic>FMR1</italic> mRNA levels were significantly elevated in the PM group compared to the control group for all three normalisation approaches (<italic>FMR1</italic>/<italic>GUS</italic>: <italic>p</italic> = 2.7×10<sup>−5</sup>; <italic>FMR1</italic>/3IC: <italic>p</italic> = 1.2×10<sup>−9</sup>; <italic>FMR1</italic>/2IC: <italic>p</italic> = 3.4×10<sup>−11</sup>). However, the most significant difference in mean values between the two groups was observed using the <italic>FMR1</italic>/2IC approach (that does not use <italic>GUS</italic> mRNA for normalisation) (<xref ref-type="fig" rid="pone.0192151.g001">Fig 1</xref>). The choice of normalisation strategy also influenced the proportion of PM females that exceeded the maximum control value for each plot (<xref ref-type="fig" rid="pone.0192151.g001">Fig 1</xref>: broken horizontal lines), with only 5 exceeding this value for <italic>FMR1</italic>/<italic>GUS</italic> (15%) and 6 for <italic>FMR1</italic>/3IC (18%) compared to 14 females for <italic>FMR1</italic>/2IC (42%) where <italic>GUS</italic> had been omitted from the normalisation equation. <italic>GUS/</italic>2IC and <italic>EIF4A2/SDHA</italic> values were not significantly elevated in the PM group compared to controls (<xref ref-type="fig" rid="pone.0192151.g001">Fig 1D and 1E</xref>; <xref ref-type="table" rid="pone.0192151.t001">Table 1</xref>). However, the <italic>GUS/</italic>2IC value showed much greater variability between individuals with interquartile range twice as large in both control and PM groups as compared to the <italic>EIF4A2/SDHA</italic> value.</p>
<fig id="pone.0192151.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192151.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Inter-group mRNA level comparison plots between 33 PM and 33 control females.</title>
<p><italic>FMR1</italic> mRNA was normalised to either <bold>(A)</bold>
<italic>GUS</italic> alone; <bold>(B)</bold> 3IC (<italic>GUS</italic>, <italic>EIF4A2</italic> and <italic>SDHA</italic>); or <bold>(C)</bold> 2IC (<italic>EIF4A2</italic> and <italic>SDHA</italic>, without <italic>GUS</italic>). <bold>(D)</bold>
<italic>GUS</italic> mRNA levels were normalised to 2IC (<italic>EIF4A2</italic> and <italic>SDHA</italic>). <bold>(E)</bold> Variability in <italic>EIF4A2</italic> to <italic>SDHA</italic> mRNA ratio (<italic>EIF4A2</italic> and <italic>SDHA)</italic>, between groups is also presented. <bold>Note:</bold> Broken horizontal lines indicate the maximum control value for each plot with percentages above this line indicating the proportion of PM females with abnormally increased <italic>FMR1</italic> mRNA levels. Control and PM CGG groups reflect range in P values correspond to <xref ref-type="table" rid="pone.0192151.t001">Table 1</xref> (30). Interquartile range (IQR); maximum value (MAX); minimum value (MIN).</p>
</caption>
<graphic xlink:href="pone.0192151.g001"></graphic>
</fig>
<table-wrap id="pone.0192151.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192151.t001</object-id>
<label>Table 1</label>
<caption>
<title>Relationships between <italic>FMR</italic>1 mRNA normalised using three different methods and CGG repeat size in PM females.</title>
</caption>
<alternatives>
<graphic id="pone.0192151.t001g" xlink:href="pone.0192151.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Outcome</th>
<th align="left" colspan="1" rowspan="1">Predictor</th>
<th align="center" colspan="1" rowspan="1">Coef</th>
<th align="center" colspan="1" rowspan="1">s.e</th>
<th align="center" colspan="1" rowspan="1"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold><italic>FMR1</italic>/<italic>GUS</italic></bold>
</td>
<td align="left" colspan="4" rowspan="1">CGG: Threshold = 79; 95% CI = (64, 93)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">CGG ≤ 79</td>
<td align="center" colspan="1" rowspan="1">0.20</td>
<td align="center" colspan="1" rowspan="1">0.19</td>
<td align="center" colspan="1" rowspan="1">0.287</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold> </bold>
</td>
<td align="left" colspan="1" rowspan="1">CGG &gt; 79</td>
<td align="center" colspan="1" rowspan="1"> 2.05</td>
<td align="center" colspan="1" rowspan="1">0.59 </td>
<td align="center" colspan="1" rowspan="1">0.001 </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold><italic>FMR1</italic>/3IC</bold>
</td>
<td align="left" colspan="4" rowspan="1">CGG: Threshold = 83; 95% CI = (73, 93)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">CGG ≤ 83</td>
<td align="center" colspan="1" rowspan="1">0.49</td>
<td align="center" colspan="1" rowspan="1">0.20</td>
<td align="center" colspan="1" rowspan="1">0.017</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold> </bold>
</td>
<td align="left" colspan="1" rowspan="1">CGG &gt; 83</td>
<td align="center" colspan="1" rowspan="1"> 3.25</td>
<td align="center" colspan="1" rowspan="1">0.723</td>
<td align="center" colspan="1" rowspan="1">3.0 x 10<sup>−5</sup> </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold><italic>FMR1</italic>/2IC</bold>
</td>
<td align="left" colspan="4" rowspan="1">CGG: Threshold = 86; 95% CI = (78, 94)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">CGG ≤ 86</td>
<td align="center" colspan="1" rowspan="1">0.82</td>
<td align="center" colspan="1" rowspan="1">0.23</td>
<td align="center" colspan="1" rowspan="1">0.001</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">CGG &gt; 86</td>
<td align="center" colspan="1" rowspan="1"> 5.07</td>
<td align="center" colspan="1" rowspan="1">0.95 </td>
<td align="center" colspan="1" rowspan="1">1.3 x 10<sup>−6</sup></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold><italic>GUS</italic>/2IC</bold>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.09</td>
<td align="center" colspan="1" rowspan="1">0.17</td>
<td align="center" colspan="1" rowspan="1">0.617</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<bold><italic>EIF4A2</italic>/<italic>SDHA</italic></bold>
</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">0.04</td>
<td align="center" colspan="1" rowspan="1">0.12</td>
<td align="center" colspan="1" rowspan="1">0.747</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p><bold>Note:</bold> Piecewise linear regression was used to find a threshold, resulting in two difference slopes above and below the threshold.</p>
</fn>
<fn id="t001fn002">
<p>Estimated regression coefficient (Coef) and standard error (s.e) were multiplied by 100. 3IC = normalisation by <italic>GUS</italic>, <italic>EIF4A2</italic> and <italic>SDHA</italic>; 2IC = normalisation by <italic>EIF4A2</italic> and <italic>SDHA</italic>, without <italic>GUS</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec009">
<title>Relationships between mRNA levels and CGG triplet repeat size in PM and control female samples</title>
<p>The influence of <italic>FMR1</italic> normalisation approach on <italic>FMR1</italic> mRNA-CGG relationships in PM and control groups was assessed. In the combined cohort of PM and control females, piecewise linear regression was used to find a threshold CGG repeat size where two different slopes could be differentiated. Below this threshold, CGG repeat size was not significantly correlated with <italic>FMR1</italic>/<italic>GUS</italic> data (<italic>p</italic> = 0.287), but was significantly correlated with data for <italic>FMR1</italic>/3IC (<italic>p</italic> = 0.017) and <italic>FMR1</italic>/2IC (<italic>p</italic> = 0.001). The strength of the relationship also varied above the threshold depending on the <italic>FMR1</italic> normalisation approach that had been used. In particular, effect size of the <italic>FMR1</italic> mRNA-CGG relationship was higher with a smaller <italic>p</italic>-value for <italic>FMR1</italic>/2IC (regression coefficient (<italic>β</italic>) = 5.07, <italic>p</italic> = 1.3 × 10<sup>−6</sup>) and <italic>FMR1</italic>/3IC (<italic>β = 3</italic>.<italic>25</italic>, <italic>p</italic> = 3 × 10<sup>−5</sup>) than it was for <italic>FMR1</italic>/<italic>GUS</italic> (<italic>β = 2</italic>.<italic>05</italic>, <italic>p</italic> = 0.001). These analyses demonstrate that removal of <italic>GUS</italic> from <italic>FMR1</italic> mRNA normalisation and/or dilution of the <italic>GUS</italic> contribution by addition of the two other internal control genes improves the <italic>FMR1</italic> mRNA-CGG size relationship and also increases the slope for this relationship. In contrast, <italic>GUS/</italic>2IC and <italic>EIF4A2/SDHA</italic> values were not significantly correlated with CGG size (<xref ref-type="fig" rid="pone.0192151.g002">Fig 2D and 2E</xref>; <xref ref-type="table" rid="pone.0192151.t001">Table 1</xref>). <italic>GUS/</italic>2IC value also showed greater variability between individuals across the full range of CGG repeat size (from control to PM) as compared to the <italic>EIF4A2/SDHA</italic> value.</p>
<fig id="pone.0192151.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0192151.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Relationship between CGG triplet repeat size and mRNA levels in the combined cohort of 33 PM and 33 control females.</title>
<p>CGG size versus <italic>FMR1</italic> mRNA normalised to either <bold>(A)</bold>
<italic>GUS</italic> alone; <bold>(B)</bold> 3IC (<italic>GUS</italic>, <italic>EIF4A2</italic> and <italic>SDHA</italic>); <bold>(C)</bold> 2IC (<italic>EIF4A2</italic> and <italic>SDHA</italic>, without <italic>GUS</italic>). CGG size versus <bold>(D)</bold>
<italic>GUS</italic> mRNA levels were normalised to 2IC (<italic>EIF4A2</italic> and <italic>SDHA</italic>); <bold>(E)</bold>
<italic>SDHA</italic>/<italic>EIF4A2</italic> mRNA ratio variability between groups is also presented. <bold>Note:</bold> Piecewise linear regression was used to find a threshold in A, B and C, resulting in two difference slopes above and below the threshold (the CGG repeat threshold is presented in bold italics). The regression coefficients and standard errors for these relationships are described in <xref ref-type="table" rid="pone.0192151.t001">Table 1</xref>.</p>
</caption>
<graphic xlink:href="pone.0192151.g002"></graphic>
</fig>
</sec>
</sec>
<sec id="sec010" sec-type="conclusions">
<title>Discussion</title>
<p>This study demonstrates that correlation between <italic>FMR1</italic> mRNA levels and CGG triplet repeat size is weakened when <italic>GUS</italic> is used as an internal control gene for mRNA analysis studies in PBMCs of PM females. Furthermore, using <italic>GUS</italic> mRNA as a sole control in the denominator led to an underestimation of <italic>FMR1</italic> mRNA levels for PM females when compared to age-matched controls. Stronger correlations were observed between <italic>FMR1</italic> mRNA and CGG triplet repeat size with the slope of the relationship increased when <italic>FMR1</italic> mRNA levels were normalised without <italic>GUS</italic> or when contributions from <italic>GUS</italic> were minimised by inclusion of the two internal control genes <italic>EIFA2</italic> and <italic>SDHA</italic>.</p>
<p>PM <italic>GUS</italic> mRNA levels (<italic>GUS</italic>/2IC) were significantly correlated with gait and verbal intelligence scores in PM but not control females [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]. However, in this study the <italic>GUS</italic>/2IC values: (i) did not significantly correlate with increased CGG triplet repeat size, and (ii) did not significantly differ between control and PM groups. <italic>GUS</italic>/2IC values were found to be more variable than the <italic>EIF4A2/SDHA</italic> ratio values in both PM and control groups between individuals. This suggested that <italic>GUS</italic> mRNA could be confounding if used to normalise <italic>FMR1</italic> mRNA levels in RT-PCR experiments (Figs <xref ref-type="fig" rid="pone.0192151.g001">1</xref> and <xref ref-type="fig" rid="pone.0192151.g002">2</xref>). This is consistent with the earlier stability study of mRNA levels for a panel of genes using the geNorm approach in another cohort [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]. This study showed that <italic>EIF4A2</italic> and <italic>SDHA</italic> mRNA levels were more stable than that of <italic>GUS</italic> in control and PM males (Supplementary Figure 1 in [<xref ref-type="bibr" rid="pone.0192151.ref030">30</xref>]).</p>
<p>In this study, <italic>FMR1</italic> mRNA level normalised to <italic>GUS</italic> alone resulted in an underestimation of <italic>FMR1</italic> mRNA in samples that had high levels of <italic>GUS</italic>/2IC mRNA. On the other hand, for samples with very low levels of internal control gene mRNA, <italic>FMR1</italic> levels were over-estimated. The inter-individual variability in <italic>GUS</italic> mRNA level detected in blood in both the control and PM groups could be due to biological or environmental factors that directly or indirectly influence the activity of the <italic>β</italic>-glucuronidase enzyme [<xref ref-type="bibr" rid="pone.0192151.ref034">34</xref>, <xref ref-type="bibr" rid="pone.0192151.ref035">35</xref>]. Furthermore, <italic>GUS</italic> mRNA stability level has been reported to be influenced by gender, age and cell type [<xref ref-type="bibr" rid="pone.0192151.ref036">36</xref>–<xref ref-type="bibr" rid="pone.0192151.ref038">38</xref>]. This limitation has been partly addressed here through the use of different internal control genes (i.e., <italic>EIF4A2</italic> and <italic>SDHA</italic>)</p>
<p>Normalisation of <italic>FMR1</italic> mRNA levels in PM and control PBMCs with <italic>EIFA2</italic> and <italic>SDHA</italic> (<italic>FMR1</italic>/2IC) has been demonstrated in previous studies examining relationships between <italic>FMR1</italic> mRNA level and phenotype [<xref ref-type="bibr" rid="pone.0192151.ref039">39</xref>–<xref ref-type="bibr" rid="pone.0192151.ref041">41</xref>]. Specifically, in twenty PM females without FXTAS, higher <italic>FMR1</italic>/2IC values correlated with mean diffusivity within the middle cerebellar peduncle determined by diffusion-weighted imaging. <italic>FMR1</italic>/2IC value was also significantly correlated with poor performance on the Paced Auditory Serial Addition Test scores indicating executive dysfunction and/or slow processing speed [<xref ref-type="bibr" rid="pone.0192151.ref039">39</xref>].</p>
<p>In summary, these findings demonstrate that <italic>GUS</italic> normalisation in PBMC studies masks the relationship between <italic>FMR1</italic> mRNA level and CGG triplet repeat size. It also artificially decreases values for <italic>FMR1</italic> mRNA level in PBMC PM data, as compared to values normalised with <italic>EIF4A2</italic> and <italic>SDHA</italic> levels. These findings may not apply to other tissue types, <italic>FMR1</italic> alleles other than PM or other age groups. Instead, the most stable combinations of optimal internal control genes should be determined for each setting separately, using validated approaches such as geNorm [<xref ref-type="bibr" rid="pone.0192151.ref042">42</xref>]. This is consistent with the fact that there are no ideal internal control genes across all settings. This is now accepted widely in other fields of genetics [<xref ref-type="bibr" rid="pone.0192151.ref029">29</xref>, <xref ref-type="bibr" rid="pone.0192151.ref043">43</xref>] and should be implemented for investigations of Fragile X-associated disorders. Utility of absolute quantification of mRNA determined through methods that do not rely on internal control normalisation, including competitive PCR [<xref ref-type="bibr" rid="pone.0192151.ref044">44</xref>] and Droplet Digital PCR [<xref ref-type="bibr" rid="pone.0192151.ref045">45</xref>], may circumvent this problem in future studies.</p>
</sec>
<sec id="sec011" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pone.0192151.s001">
<label>S1 Table</label>
<caption>
<title><italic>FMR1</italic>, <italic>GUS</italic>, <italic>SDHA</italic> and <italic>EIF4A2</italic> mRNA data obtained using relative standard curve real-time PCR method from peripheral blood mononuclear cell RNA of 33 PM and 33 control females.</title>
<p>(XLSX)</p>
</caption>
<media xlink:href="pone.0192151.s001.xlsx">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>This study was supported by an Australian Research Council (ARC) Discovery grant (DP110103346) to K.M.C, an Australian Postgraduate Award Scholarship, Monash University Faculty of Medicine, Nursing and Health Sciences Bridging Postdoctoral Fellowship and NHMRC Early Career fellowship to C.M.K. (no. 1112934); a Next Generation Clinical Researchers Program—Career Development Fellowship, funded by the Medical Research Future Fund (MRFF 1141334) to D.E.G.; and by the Victorian Government’s Operational Infrastructure Support Program, with the salaries for the molecular component supported by NHMRC project grants (no. 104299, and no. 1103389 to H.R.S. and D.E.G.) and Murdoch Children’s Research Institute, Royal Children’s Hospital Foundation (D.E.G.). The authors thank the Fragile X Association of Australia and Fragile X Alliance for supporting recruitment. They also sincerely thank all the women who participated in this research.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0192151.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Seltzer</surname><given-names>MM</given-names></name>, <name><surname>Baker</surname><given-names>MW</given-names></name>, <name><surname>Hong</surname><given-names>J</given-names></name>, <name><surname>Maenner</surname><given-names>M</given-names></name>, <name><surname>Greenberg</surname><given-names>J</given-names></name>, <name><surname>Mandel</surname><given-names>D</given-names></name>. <article-title>Prevalence of CGG expansions of the <italic>FMR1</italic> gene in a US population-based sample</article-title>. <source/>Am J Med Genet B Neuropsychiatr Genet. <year>2012</year>;<volume>159B</volume>(<issue>5</issue>):<fpage>589</fpage>–<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ajmg.b.32065">10.1002/ajmg.b.32065</ext-link></comment>
<pub-id pub-id-type="pmid">22619118</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Heitz</surname><given-names>D</given-names></name>, <name><surname>Devys</surname><given-names>D</given-names></name>, <name><surname>Imbert</surname><given-names>G</given-names></name>, <name><surname>Kretz</surname><given-names>C</given-names></name>, <name><surname>Mandel</surname><given-names>JL</given-names></name>. <article-title>Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation</article-title>. <source/>J Med Genet. <year>1992</year>;<volume>29</volume>(<issue>11</issue>):<fpage>794</fpage>–<lpage>801</lpage>. <pub-id pub-id-type="pmid">1453430</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref003">
<label>3</label>
<mixed-citation publication-type="journal"><name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Berry-Kravis</surname><given-names>E</given-names></name>, <name><surname>Kaufmann</surname><given-names>WE</given-names></name>, <name><surname>Ono</surname><given-names>MY</given-names></name>, <name><surname>Tartaglia</surname><given-names>N</given-names></name>, <name><surname>Lachiewicz</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Advances in the Treatment of Fragile X Syndrome</article-title>. <source/>Pediatrics. <year>2009</year>;<volume>123</volume>(<issue>1</issue>):<fpage>378</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1542/peds.2008-0317">10.1542/peds.2008-0317</ext-link></comment>
<pub-id pub-id-type="pmid">19117905</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Leehey</surname><given-names>M</given-names></name>, <name><surname>Heinrichs</surname><given-names>W</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Wilson</surname><given-names>R</given-names></name>, <name><surname>Hills</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X</article-title>. <source/>Neurology. <year>2001</year>;<volume>57</volume>(<issue>1</issue>):<fpage>127</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="pmid">11445641</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Sherman</surname><given-names>SL</given-names></name>. <article-title>Premature ovarian failure in the fragile X syndrome</article-title>. <source/>Am J Med Genet. <year>2000</year>;<volume>97</volume>(<issue>3</issue>):<fpage>189</fpage>–<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/1096-8628(200023)97:3&lt;189::AID-AJMG1036&gt;3.0.CO;2-J">10.1002/1096-8628(200023)97:3&lt;189::AID-AJMG1036&gt;3.0.CO;2-J</ext-link></comment>
<pub-id pub-id-type="pmid">11449487</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Pastori</surname><given-names>C</given-names></name>, <name><surname>Peschansky</surname><given-names>VJ</given-names></name>, <name><surname>Barbouth</surname><given-names>D</given-names></name>, <name><surname>Mehta</surname><given-names>A</given-names></name>, <name><surname>Silva</surname><given-names>JP</given-names></name>, <name><surname>Wahlestedt</surname><given-names>C</given-names></name>. <article-title>Comprehensive analysis of the transcriptional landscape of the human <italic>FMR1</italic> gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome</article-title>. <source/>Hum Genet. <year>2014</year>;<volume>133</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00439-013-1356-6">10.1007/s00439-013-1356-6</ext-link></comment>
<pub-id pub-id-type="pmid">24005575</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Loesch</surname><given-names>DZ</given-names></name>, <name><surname>Godler</surname><given-names>DE</given-names></name>, <name><surname>Evans</surname><given-names>A</given-names></name>, <name><surname>Bui</surname><given-names>QM</given-names></name>, <name><surname>Gehling</surname><given-names>F</given-names></name>, <name><surname>Kotschet</surname><given-names>KE</given-names></name>, <etal>et al</etal>
<article-title>Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the <italic>FMR1</italic> gene in patients with parkinsonism</article-title>. <source/>Genet Med. <year>2011</year>;<volume>13</volume>(<issue>5</issue>):<fpage>392</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/GIM.0b013e3182064362">10.1097/GIM.0b013e3182064362</ext-link></comment>
<pub-id pub-id-type="pmid">21270637</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Hukema</surname><given-names>RK</given-names></name>, <name><surname>Buijsen</surname><given-names>RA</given-names></name>, <name><surname>Raske</surname><given-names>C</given-names></name>, <name><surname>Severijnen</surname><given-names>LA</given-names></name>, <name><surname>Nieuwenhuizen-Bakker</surname><given-names>I</given-names></name>, <name><surname>Minneboo</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo</article-title>. <source/>Cell Cycle. <year>2014</year>;<volume>13</volume>(<issue>16</issue>):<fpage>2600</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/15384101.2014.943112">10.4161/15384101.2014.943112</ext-link></comment>
<pub-id pub-id-type="pmid">25486200</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Todd Peter</surname><given-names>K</given-names></name>, <name><surname>Oh Seok</surname><given-names>Y</given-names></name>, <name><surname>Krans</surname><given-names>A</given-names></name>, <name><surname>He</surname><given-names>F</given-names></name>, <name><surname>Sellier</surname><given-names>C</given-names></name>, <name><surname>Frazer</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome</article-title>. <source/>Neuron. <year>2013</year>;<volume>78</volume>(<issue>3</issue>):<fpage>440</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neuron.2013.03.026">10.1016/j.neuron.2013.03.026</ext-link></comment>
<pub-id pub-id-type="pmid">23602499</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Taylor</surname><given-names>AK</given-names></name>, <name><surname>Gane</surname><given-names>LW</given-names></name>, <name><surname>Godfrey</surname><given-names>TE</given-names></name>, <name><surname>Hagerman</surname><given-names>PJ</given-names></name>. <article-title>Elevated levels of <italic>FMR1</italic> mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome</article-title>. <source/>Am J Hum Genet. <year>2000</year>;<volume>66</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/302720">10.1086/302720</ext-link></comment>
<pub-id pub-id-type="pmid">10631132</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Hagerman</surname><given-names>P</given-names></name>. <article-title>Fragile X-associated tremor/ataxia syndrome—features, mechanisms and management</article-title>. <source/>Nature reviews Neurology. <year>2016</year>;<volume>12</volume>(<issue>7</issue>):<fpage>403</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrneurol.2016.82">10.1038/nrneurol.2016.82</ext-link></comment>
<pub-id pub-id-type="pmid">27340021</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>Hagerman</surname><given-names>R</given-names></name>, <name><surname>Hagerman</surname><given-names>P</given-names></name>. <article-title>Advances in clinical and molecular understanding of the <italic>FMR1</italic> premutation and fragile X-associated tremor/ataxia syndrome</article-title>. <source/>Lancet Neurol. <year>2013</year>;<volume>12</volume>(<issue>8</issue>):<fpage>786</fpage>–<lpage>98</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1474-4422(13)70125-X">10.1016/S1474-4422(13)70125-X</ext-link></comment>
<pub-id pub-id-type="pmid">23867198</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Hashem</surname><given-names>V</given-names></name>, <name><surname>Galloway</surname><given-names>JN</given-names></name>, <name><surname>Mori</surname><given-names>M</given-names></name>, <name><surname>Willemsen</surname><given-names>R</given-names></name>, <name><surname>Oostra</surname><given-names>BA</given-names></name>, <name><surname>Paylor</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Ectopic expression of CGG containing mRNA is neurotoxic in mammals</article-title>. <source/>Hum Mol Genet. <year>2009</year>;<volume>18</volume>(<issue>13</issue>):<fpage>2443</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddp182">10.1093/hmg/ddp182</ext-link></comment>
<pub-id pub-id-type="pmid">19377084</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Greco</surname><given-names>CM</given-names></name>, <name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Chudley</surname><given-names>AE</given-names></name>, <name><surname>Del Bigio</surname><given-names>MR</given-names></name>, <name><surname>Jacquemont</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers</article-title>. <source/>Brain. <year>2002</year>;<volume>125</volume>(<issue>Pt 8</issue>):<fpage>1760</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="pmid">12135967</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Greco</surname><given-names>CM</given-names></name>, <name><surname>Berman</surname><given-names>RF</given-names></name>, <name><surname>Martin</surname><given-names>RM</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Schwartz</surname><given-names>PH</given-names></name>, <name><surname>Chang</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>. <source/>Brain. <year>2006</year>;<volume>129</volume>(<issue>Pt 1</issue>):<fpage>243</fpage>–<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/brain/awh683">10.1093/brain/awh683</ext-link></comment>
<pub-id pub-id-type="pmid">16332642</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Iwahashi</surname><given-names>CK</given-names></name>, <name><surname>Yasui</surname><given-names>DH</given-names></name>, <name><surname>An</surname><given-names>HJ</given-names></name>, <name><surname>Greco</surname><given-names>CM</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Nannen</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Protein composition of the intranuclear inclusions of FXTAS</article-title>. <source/>Brain. <year>2006</year>;<volume>129</volume>(<issue>Pt 1</issue>):<fpage>256</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/brain/awh650">10.1093/brain/awh650</ext-link></comment>
<pub-id pub-id-type="pmid">16246864</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Willemsen</surname><given-names>R</given-names></name>, <name><surname>Hoogeveen-Westerveld</surname><given-names>M</given-names></name>, <name><surname>Reis</surname><given-names>S</given-names></name>, <name><surname>Holstege</surname><given-names>J</given-names></name>, <name><surname>Severijnen</surname><given-names>L-AWFM</given-names></name>, <name><surname>Nieuwenhuizen</surname><given-names>IM</given-names></name>, <etal>et al</etal>
<article-title>The <italic>FMR1</italic> CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome</article-title>. <source/>Hum Mol Genet. <year>2003</year>;<volume>12</volume>(<issue>9</issue>):<fpage>949</fpage>–<lpage>59</lpage>. <pub-id pub-id-type="pmid">12700164</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Wenzel</surname><given-names>HJ</given-names></name>, <name><surname>Hunsaker</surname><given-names>MR</given-names></name>, <name><surname>Greco</surname><given-names>CM</given-names></name>, <name><surname>Willemsen</surname><given-names>R</given-names></name>, <name><surname>Berman</surname><given-names>RF</given-names></name>. <article-title>Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation</article-title>. <source/>Brain Res. <year>2010</year>;<volume>1318</volume>:<fpage>155</fpage>–<lpage>66</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.brainres.2009.12.077">10.1016/j.brainres.2009.12.077</ext-link></comment>
<pub-id pub-id-type="pmid">20051238</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>JY</given-names></name>, <name><surname>Hessl</surname><given-names>D</given-names></name>, <name><surname>Schneider</surname><given-names>A</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Hagerman</surname><given-names>RJ</given-names></name>, <name><surname>Rivera</surname><given-names>SM</given-names></name>. <article-title>Fragile X-Associated Tremor/Ataxia Syndrome: Influence of the <italic>FMR1</italic> Gene on Motor Fiber Tracts in Males With Normal and Premutation Alleles</article-title>. <source/>JAMA Neurol. <year>2013</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Hocking</surname><given-names>DR</given-names></name>, <name><surname>Birch</surname><given-names>RC</given-names></name>, <name><surname>Bui</surname><given-names>QM</given-names></name>, <name><surname>Menant</surname><given-names>JC</given-names></name>, <name><surname>Lord</surname><given-names>SR</given-names></name>, <name><surname>Georgiou-Karistianis</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Cerebellar volume mediates the relationship between <italic>FMR1</italic> mRNA levels and voluntary step initiation in males with the premutation</article-title>. <source/>Neurobiol Aging. <year>2016</year>;<volume>50</volume>:<fpage>5</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.neurobiolaging.2016.10.017">10.1016/j.neurobiolaging.2016.10.017</ext-link></comment>
<pub-id pub-id-type="pmid">27837676</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Niu</surname><given-names>YQ</given-names></name>, <name><surname>Yang</surname><given-names>JC</given-names></name>, <name><surname>Hall</surname><given-names>DA</given-names></name>, <name><surname>Leehey</surname><given-names>MA</given-names></name>, <name><surname>Tassone</surname><given-names>F</given-names></name>, <name><surname>Olichney</surname><given-names>JM</given-names></name>, <etal>et al</etal>
<article-title>Parkinsonism in fragile X-associated tremor/ataxia syndrome (FXTAS): Revisited</article-title>. <source/>Parkinsonism Relat Disord. <year>2014</year>;<volume>18</volume>(<issue>14</issue>):<fpage>006</fpage>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Birch</surname><given-names>RC</given-names></name>, <name><surname>Hocking</surname><given-names>DR</given-names></name>, <name><surname>Cornish</surname><given-names>KM</given-names></name>, <name><surname>Menant</surname><given-names>JC</given-names></name>, <name><surname>Georgiou-Karistianis</surname><given-names>N</given-names></name>, <name><surname>Godler</surname><given-names>DE</given-names></name>, <etal>et al</etal>
<article-title>Preliminary evidence of an effect of cerebellar volume on postural sway in <italic>FMR1</italic> premutation males</article-title>. <source/>Genes Brain Behav. <year>2015</year>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Leehey</surname><given-names>MA</given-names></name>, <name><surname>Berry-Kravis</surname><given-names>E</given-names></name>, <name><surname>Goetz</surname><given-names>CG</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Hall</surname><given-names>DA</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title><italic>FMR1</italic> CGG repeat length predicts motor dysfunction in premutation carriers</article-title>. <source/>Neurology. <year>2008</year>;<fpage>70</fpage>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>J</given-names></name>, <name><surname>Bian</surname><given-names>L</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Dong</surname><given-names>Z</given-names></name>, <name><surname>Gao</surname><given-names>X</given-names></name>, <name><surname>Luan</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Identification of genes for normalization of quantitative real-time PCR data in ovarian tissues</article-title>. <source/>Acta biochimica et biophysica Sinica. <year>2010</year>;<volume>42</volume>(<issue>8</issue>):<fpage>568</fpage>–<lpage>74</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/abbs/gmq062">10.1093/abbs/gmq062</ext-link></comment>
<pub-id pub-id-type="pmid">20705598</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Turabelidze</surname><given-names>A</given-names></name>, <name><surname>Guo</surname><given-names>S</given-names></name>, <name><surname>DiPietro</surname><given-names>LA</given-names></name>. <article-title>Importance of housekeeping gene selection for accurate reverse transcription-quantitative polymerase chain reaction in a wound healing model</article-title>. <source/>Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society. <year>2010</year>;<volume>18</volume>(<issue>5</issue>):<fpage>460</fpage>–<lpage>6</lpage>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Valente</surname><given-names>V</given-names></name>, <name><surname>Teixeira</surname><given-names>SA</given-names></name>, <name><surname>Neder</surname><given-names>L</given-names></name>, <name><surname>Okamoto</surname><given-names>OK</given-names></name>, <name><surname>Oba-Shinjo</surname><given-names>SM</given-names></name>, <name><surname>Marie</surname><given-names>SK</given-names></name>, <etal>et al</etal>
<article-title>Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR</article-title>. <source/>BMC molecular biology. <year>2009</year>;<volume>10</volume>:<fpage>17</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2199-10-17">10.1186/1471-2199-10-17</ext-link></comment>
<pub-id pub-id-type="pmid">19257903</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Vega-Sanchez</surname><given-names>R</given-names></name>, <name><surname>Arenas-Hernandez</surname><given-names>M</given-names></name>, <name><surname>Vazquez-Perez</surname><given-names>JA</given-names></name>, <name><surname>Moreno-Valencia</surname><given-names>Y</given-names></name>, <name><surname>Gomez-Lopez</surname><given-names>N</given-names></name>. <article-title>Evaluation of reference genes for expression studies in leukocytes from term human pregnancy</article-title>. <source/>Placenta. <year>2015</year>;<volume>36</volume>(<issue>2</issue>):<fpage>240</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.placenta.2014.11.010">10.1016/j.placenta.2014.11.010</ext-link></comment>
<pub-id pub-id-type="pmid">25484264</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Ferraz</surname><given-names>FB</given-names></name>, <name><surname>Fernandez</surname><given-names>JH</given-names></name>. <article-title>Selection and validation of reference house-keeping genes in the J774A1 macrophage cell line for quantitative real-time PCR</article-title>. <source/>Genet Mol Res. <year>2016</year>;<volume>15</volume>(<issue>1</issue>):<fpage>15017720</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4238/gmr.15017720">10.4238/gmr.15017720</ext-link></comment>
<pub-id pub-id-type="pmid">26985962</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Lossos</surname><given-names>IS</given-names></name>, <name><surname>Czerwinski</surname><given-names>DK</given-names></name>, <name><surname>Wechser</surname><given-names>MA</given-names></name>, <name><surname>Levy</surname><given-names>R</given-names></name>. <article-title>Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies</article-title>. <source/>Leukemia. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>789</fpage>–<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sj.leu.2402880">10.1038/sj.leu.2402880</ext-link></comment>
<pub-id pub-id-type="pmid">12682639</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Kraan</surname><given-names>CM</given-names></name>, <name><surname>Cornish</surname><given-names>KM</given-names></name>, <name><surname>Bui</surname><given-names>QM</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Slater</surname><given-names>HR</given-names></name>, <name><surname>Godler</surname><given-names>DE</given-names></name>. <article-title>beta-glucuronidase mRNA levels are correlated with gait and working memory in premutation females: understanding the role of <italic>FMR1</italic> premutation alleles</article-title>. <source/>Scientific reports. <year>2016</year>;<volume>6</volume>:<fpage>29366</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep29366">10.1038/srep29366</ext-link></comment>
<pub-id pub-id-type="pmid">27387142</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>L</given-names></name>, <name><surname>Hadd</surname><given-names>A</given-names></name>, <name><surname>Sah</surname><given-names>S</given-names></name>, <name><surname>Filipovic-Sadic</surname><given-names>S</given-names></name>, <name><surname>Krosting</surname><given-names>J</given-names></name>, <name><surname>Sekinger</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis</article-title>. <source/>J Mol Diagn. <year>2010</year>;<volume>12</volume>(<issue>5</issue>):<fpage>589</fpage>–<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2353/jmoldx.2010.090227">10.2353/jmoldx.2010.090227</ext-link></comment>
<pub-id pub-id-type="pmid">20616364</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Pietrobono</surname><given-names>R</given-names></name>, <name><surname>Tabolacci</surname><given-names>E</given-names></name>, <name><surname>Zalfa</surname><given-names>F</given-names></name>, <name><surname>Zito</surname><given-names>I</given-names></name>, <name><surname>Terracciano</surname><given-names>A</given-names></name>, <name><surname>Moscato</surname><given-names>U</given-names></name>, <etal>et al</etal>
<article-title>Molecular dissection of the events leading to inactivation of the <italic>FMR1</italic> gene</article-title>. <source/>Hum Mol Genet. <year>2005</year>;<volume>14</volume>(<issue>2</issue>):<fpage>267</fpage>–<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/hmg/ddi024">10.1093/hmg/ddi024</ext-link></comment>
<pub-id pub-id-type="pmid">15563507</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Godler</surname><given-names>DE</given-names></name>, <name><surname>Loesch</surname><given-names>DZ</given-names></name>, <name><surname>Huggins</surname><given-names>R</given-names></name>, <name><surname>Gordon</surname><given-names>L</given-names></name>, <name><surname>Slater</surname><given-names>HR</given-names></name>, <name><surname>Gehling</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Improved methodology for assessment of mRNA levels in blood of patients with <italic>FMR1</italic> related disorders</article-title>. <source/>BMC Clin Pathol. <year>2009</year>;<volume>9</volume>(<issue>5</issue>):<fpage>1472</fpage>–<lpage>6890</lpage>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Tappel</surname><given-names>AL</given-names></name>, <name><surname>Dillard</surname><given-names>CJ</given-names></name>. <article-title>Inhibition of beta-glucuronidase by cholesterol and retinol</article-title>. <source/>J Biol Chem. <year>1967</year>;<volume>242</volume>(<issue>10</issue>):<fpage>2463</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">6026237</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Perez</surname><given-names>A</given-names></name>, <name><surname>Gonzalez-Manzano</surname><given-names>S</given-names></name>, <name><surname>Jimenez</surname><given-names>R</given-names></name>, <name><surname>Perez-Abud</surname><given-names>R</given-names></name>, <name><surname>Haro</surname><given-names>JM</given-names></name>, <name><surname>Osuna</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>The flavonoid quercetin induces acute vasodilator effects in healthy volunteers: correlation with beta-glucuronidase activity</article-title>. <source/>Pharmacological research. <year>2014</year>;<volume>89</volume>:<fpage>11</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.phrs.2014.07.005">10.1016/j.phrs.2014.07.005</ext-link></comment>
<pub-id pub-id-type="pmid">25076013</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Lombardo</surname><given-names>A</given-names></name>, <name><surname>Bairati</surname><given-names>C</given-names></name>, <name><surname>Goi</surname><given-names>G</given-names></name>, <name><surname>Roggi</surname><given-names>C</given-names></name>, <name><surname>Maccarini</surname><given-names>L</given-names></name>, <name><surname>Bollini</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Plasma lysosomal glycohydrolases in a general population</article-title>. <source/>Clin Chim Acta. <year>1996</year>;<volume>247</volume>(<issue>1–2</issue>):<fpage>39</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="pmid">8920225</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Cobben</surname><given-names>NA</given-names></name>, <name><surname>Drent</surname><given-names>M</given-names></name>, <name><surname>De Vries</surname><given-names>J</given-names></name>, <name><surname>Wouters</surname><given-names>EF</given-names></name>, <name><surname>Van Dieijen-Visser</surname><given-names>MP</given-names></name>, <name><surname>Henderson</surname><given-names>RF</given-names></name>. <article-title>Serum beta-glucuronidase activity in a population of ex-coalminers</article-title>. <source/>Clinical biochemistry. <year>1999</year>;<volume>32</volume>(<issue>8</issue>):<fpage>659</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="pmid">10638950</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Ueyama</surname><given-names>J</given-names></name>, <name><surname>Satoh</surname><given-names>T</given-names></name>, <name><surname>Kondo</surname><given-names>T</given-names></name>, <name><surname>Takagi</surname><given-names>K</given-names></name>, <name><surname>Shibata</surname><given-names>E</given-names></name>, <name><surname>Goto</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Beta-glucuronidase activity is a sensitive biomarker to assess low-level organophosphorus insecticide exposure</article-title>. <source/>Toxicology letters. <year>2010</year>;<volume>193</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxlet.2009.12.009">10.1016/j.toxlet.2009.12.009</ext-link></comment>
<pub-id pub-id-type="pmid">20026393</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Shelton</surname><given-names>AL</given-names></name>, <name><surname>Cornish</surname><given-names>KM</given-names></name>, <name><surname>Godler</surname><given-names>D</given-names></name>, <name><surname>Bui</surname><given-names>QM</given-names></name>, <name><surname>Kolbe</surname><given-names>S</given-names></name>, <name><surname>Fielding</surname><given-names>J</given-names></name>. <article-title>White matter microstructure, cognition, and molecular markers in fragile X premutation females</article-title>. <source/>Neurology. <year>2017</year>.</mixed-citation>
</ref>
<ref id="pone.0192151.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Shelton</surname><given-names>AL</given-names></name>, <name><surname>Cornish</surname><given-names>KM</given-names></name>, <name><surname>Kolbe</surname><given-names>S</given-names></name>, <name><surname>Clough</surname><given-names>M</given-names></name>, <name><surname>Slater</surname><given-names>HR</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>Brain structure and intragenic DNA methylation are correlated, and predict executive dysfunction in fragile X premutation females</article-title>. <source/>Transl Psychiatry. <year>2016</year>;<volume>6</volume>(<issue>12</issue>):<fpage>e984</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/tp.2016.250">10.1038/tp.2016.250</ext-link></comment>
<pub-id pub-id-type="pmid">27959330</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Nyquist</surname><given-names>PA</given-names></name>, <name><surname>Hagerman</surname><given-names>R</given-names></name>. <article-title>Genetics, white matter, and cognition: The effects of methylation on <italic>FMR1</italic></article-title>. <source/>Neurology. <year>2017</year>;<volume>88</volume>(<issue>22</issue>):<fpage>2070</fpage>–<lpage>1</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1212/WNL.0000000000003994">10.1212/WNL.0000000000003994</ext-link></comment>
<pub-id pub-id-type="pmid">28476761</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Vandesompele</surname><given-names>J</given-names></name>, <name><surname>De Preter</surname><given-names>K</given-names></name>, <name><surname>Pattyn</surname><given-names>F</given-names></name>, <name><surname>Poppe</surname><given-names>B</given-names></name>, <name><surname>Van Roy</surname><given-names>N</given-names></name>, <name><surname>De Paepe</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes</article-title>. <source/>Genome biology. <year>2002</year>;<volume>3</volume>(<issue>7</issue>).</mixed-citation>
</ref>
<ref id="pone.0192151.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Bennani-Baiti</surname><given-names>B</given-names></name>, <name><surname>Toegel</surname><given-names>S</given-names></name>, <name><surname>Viernstein</surname><given-names>H</given-names></name>, <name><surname>Urban</surname><given-names>E</given-names></name>, <name><surname>Noe</surname><given-names>CR</given-names></name>, <name><surname>Bennani-Baiti</surname><given-names>IM</given-names></name>. <article-title>Inflammation Modulates RLIP76/RALBP1 Electrophile-Glutathione Conjugate Transporter and Housekeeping Genes in Human Blood-Brain Barrier Endothelial Cells</article-title>. <source/>PLoS ONE. <year>2015</year>;<volume>10</volume>(<issue>9</issue>).</mixed-citation>
</ref>
<ref id="pone.0192151.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Godler</surname><given-names>DE</given-names></name>, <name><surname>Stein</surname><given-names>AN</given-names></name>, <name><surname>Bakharevski</surname><given-names>O</given-names></name>, <name><surname>Lindsay</surname><given-names>MM</given-names></name>, <name><surname>Ryan</surname><given-names>PF</given-names></name>. <article-title>Parathyroid hormone-related peptide expression in rat collagen-induced arthritis</article-title>. <source/>Rheumatology (Oxford). <year>2005</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1122</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">15901905</pub-id></mixed-citation>
</ref>
<ref id="pone.0192151.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Hindson</surname><given-names>CM</given-names></name>, <name><surname>Chevillet</surname><given-names>JR</given-names></name>, <name><surname>Briggs</surname><given-names>HA</given-names></name>, <name><surname>Gallichotte</surname><given-names>EN</given-names></name>, <name><surname>Ruf</surname><given-names>IK</given-names></name>, <name><surname>Hindson</surname><given-names>BJ</given-names></name>, <etal>et al</etal>
<article-title>Absolute quantification by droplet digital PCR versus analog real-time PCR</article-title>. <source/>Nature methods. <year>2013</year>;<volume>10</volume>(<issue>10</issue>):<fpage>1003</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nmeth.2633">10.1038/nmeth.2633</ext-link></comment>
<pub-id pub-id-type="pmid">23995387</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>